Common Contracts
4 similar Underwriting Agreement contracts by Aflac Inc, Amgen Inc, Vulcan Materials CO
Aflac Incorporated ¥12,400,000,000 0.300% Senior Notes due 2025 ¥13,300,000,000 0.550% Senior Notes due 2030 ¥20,700,000,000 0.750% Senior Notes due 2032 ¥10,600,000,000 0.830% Senior Notes due 2035 Underwriting AgreementUnderwriting Agreement • March 12th, 2020 • Aflac Inc • Accident & health insurance • New York
Aflac Incorporated, a Georgia corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom Mizuho Securities USA LLC, Morgan Stanley & Co. International plc and SMBC Nikko Securities America, Inc. are acting as Representatives (the “Representatives”), an aggregate of ¥12,400,000,000 principal amount of the 0.300% Senior Notes due 2025 (the “2025 Notes”), ¥13,300,000,000 principal amount of the 0.550% Senior Notes due 2030 (the “2030 Notes”), ¥20,700,000,000 principal amount of the 0.750% Senior Notes due 2032 (the “2032 Notes”) and ¥10,600,000,000 principal amount of the 0.830% Senior Notes due 2035 (the “2035 Notes” and together with the 2025 Notes, the 2030 Notes and the 2032 Notes, the “Securities”). The 2025 Notes will be issued under the Senior Debt Indenture, dated as of May 21, 2009 (the “Senior Debt Indenture”), as supplemented by the Twenty-Third Supplem
Aflac Incorporated ¥12,600,000,000 0.500% Senior Notes due 2029 ¥9,300,000,000 0.843% Senior Notes due 2031 ¥9,800,000,000 0.934% Senior Notes due 2034 ¥6,300,000,000 1.122% Senior Notes due 2039 Underwriting AgreementUnderwriting Agreement • December 17th, 2019 • Aflac Inc • Accident & health insurance • New York
Aflac Incorporated, a Georgia corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs International, Mizuho Securities USA LLC, Morgan Stanley & Co. International plc, and SMBC Nikko Securities America, Inc. are acting as Representatives (the “Representatives”), an aggregate of ¥12,600,000,000 principal amount of the 0.500% Senior Notes due 2029 (the “2029 Notes”), ¥9,300,000,000 principal amount of the 0.843% Senior Notes due 2031 (the “2031 Notes”), ¥9,800,000,000 principal amount of the 0.934% Senior Notes due 2034 (the “2034 Notes”), and ¥6,300,000,000 principal amount of the 1.122% Senior Notes due 2039 (the “2039 Notes” and together with the 2029 Notes, the 2031 Notes, and the 2034 Notes, the “Securities”). The 2029 Notes will be issued under the Senior Debt Indenture, dated as of May 21, 2009 (the “Senior Debt Indenture”), as supplemente
Vulcan Materials Company Floating Rates Notes due 2020 Underwriting AgreementUnderwriting Agreement • June 15th, 2017 • Vulcan Materials CO • Mining & quarrying of nonmetallic minerals (no fuels)
Vulcan Materials Company, a New Jersey corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, (i) an aggregate of $250,000,000 principal amount of Floating Rate Notes due 2020 (the “2020 Floating Rate Notes”); (ii) an aggregate of $50,000,000 principal amount of 3.900% Notes due 2027 (the “2027 Notes”) and (iii) an aggregate of $700,000,000 principal amount of 4.500% Notes due 2047 (the “2047 Notes” and, together with the 2020 Floating Rate Notes and the 2027 Notes, the “Securities”).
AMGEN INC. $1,000,000,000 1.875% SENIOR NOTES DUE 2014 $1,000,000,000 2.50% SENIOR NOTES DUE 2016 $1,750,000,000 3.875% SENIOR NOTES DUE 2021 $2,250,000,000 5.15% SENIOR NOTES DUE 2041 Underwriting AgreementUnderwriting Agreement • November 10th, 2011 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,000,000,000 principal amount of the 1.875% Senior Notes due 2014 of the Company (the “2014 Notes”), an aggregate of $1,000,000,000 principal amount of the 2.50% Senior Notes due 2016 of the Company (the “2016 Notes”), an aggregate of $1,750,000,000 principal amount of the 3.875% Senior Notes due 2021 of the Company (the “2021 Notes”) and an aggregate of $2,250,000,000 principal amount of the 5.15% Senior Notes due 2041 of the Company (the “2041 Notes”, and together with the 2014 Notes, the 2016 Notes and the 2021 Notes, collectively, the “Securities”) to be issued pursuant to the provisions of an Indenture, dated as of August 4, 2003 (the “Indenture”), between the Company and the Bank of New York Mellon, as successor to JPMorgan Chase Bank, N.A., as Trustee (the “Trustee”
